TY - JOUR
T1 - New developments in antibody therapy for acute myeloid leukemia
AU - Tomblyn, Marcie R.
AU - Tallman, Martin S.
PY - 2003/8
Y1 - 2003/8
N2 - In the past three decades, improvements in the treatment of acute myeloid leukemia (AML) have increased survival in patients younger than 55 years without significant survival impact in older individuals. Unfortunately, many patients, regardless of age at diagnosis, will eventually die from their disease. Advances in the development of targeted therapies have proven beneficial in chronic myeloid leukemia and lymphoma. Gemtuzumab ozogamicin (GO; Mylotarg, Wyeth-Ayerst, St Davids, PA), a monoclonal antibody conjugated to calicheamicin, targets the CD33 antigen found on the surface of more than 80% of AML leukemic blasts. GO is approved for relapsed disease in patients older than 60 years, but is being evaluated in combination with chemotherapy, in the setting of hematopoietic stem cell transplant, and in high-risk myelodysplasia.
AB - In the past three decades, improvements in the treatment of acute myeloid leukemia (AML) have increased survival in patients younger than 55 years without significant survival impact in older individuals. Unfortunately, many patients, regardless of age at diagnosis, will eventually die from their disease. Advances in the development of targeted therapies have proven beneficial in chronic myeloid leukemia and lymphoma. Gemtuzumab ozogamicin (GO; Mylotarg, Wyeth-Ayerst, St Davids, PA), a monoclonal antibody conjugated to calicheamicin, targets the CD33 antigen found on the surface of more than 80% of AML leukemic blasts. GO is approved for relapsed disease in patients older than 60 years, but is being evaluated in combination with chemotherapy, in the setting of hematopoietic stem cell transplant, and in high-risk myelodysplasia.
UR - http://www.scopus.com/inward/record.url?scp=0042737441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042737441&partnerID=8YFLogxK
U2 - 10.1016/S0093-7754(03)00234-3
DO - 10.1016/S0093-7754(03)00234-3
M3 - Article
C2 - 12939719
AN - SCOPUS:0042737441
SN - 0093-7754
VL - 30
SP - 502
EP - 508
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 4
ER -